Search research articles
Contact Us
Filters
Showing results (61-70 of 89) with videos related to
Page
of 9
Sort By:
Journal of Patient Experience
|
February 21, 2022
Impact of the COVID-19 Pandemic on Cancer Care and Quality of Life for Patients With Breast and Gynecologic Malignancies: A Single-Center Survey-Based Study
Natalie F Berger, Brittney S Zimmerman, Danielle Seidman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2014
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases
Sylvia Adams, Yelena Novik, Ruth Oratz, et al.
The Journal of Dermatologic Surgery and Oncology
|
January 1, 1991
Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome
A D Tiersten, C M Grin, A W Kopf, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 1, 2006
Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer
A Tiersten, M Selleck, D H Smith, et al.
Gynecologic Oncology
|
June 16, 2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study
Amy D Tiersten, Michael W Sill, Danielle Knight, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Clinical Breast Cancer
|
July 6, 2024
Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Nicole Casasanta, Rima Patel, Samantha Raymond, et al.
Gynecologic Oncology
|
December 10, 2016
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Fernanda Musa, Bhavana Pothuri, Stephanie V Blank, et al.
Gynecologic Oncology
|
May 26, 2009
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
Harriet O Smith, James Moon, Sharon P Wilczynski, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 89) with videos related to
Sort By:
Page
of 9
Journal of Patient Experience
|
February 21, 2022
Impact of the COVID-19 Pandemic on Cancer Care and Quality of Life for Patients With Breast and Gynecologic Malignancies: A Single-Center Survey-Based Study
Natalie F Berger, Brittney S Zimmerman, Danielle Seidman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2014
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases
Sylvia Adams, Yelena Novik, Ruth Oratz, et al.
The Journal of Dermatologic Surgery and Oncology
|
January 1, 1991
Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome
A D Tiersten, C M Grin, A W Kopf, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 1, 2006
Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer
A Tiersten, M Selleck, D H Smith, et al.
Gynecologic Oncology
|
June 16, 2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study
Amy D Tiersten, Michael W Sill, Danielle Knight, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Clinical Breast Cancer
|
July 6, 2024
Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Nicole Casasanta, Rima Patel, Samantha Raymond, et al.
Gynecologic Oncology
|
December 10, 2016
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Fernanda Musa, Bhavana Pothuri, Stephanie V Blank, et al.
Gynecologic Oncology
|
May 26, 2009
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
Harriet O Smith, James Moon, Sharon P Wilczynski, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Page
of 9